Edwards Lifesciences (EW) Q4 2025 earnings review
TAVR Accelerates, But Costs Weigh on Profitability
Edwards ended FY25 with accelerating momentum, delivering 13.3% revenue growth in Q4 driven by a resurgence in TAVR (+12%) and continued hyper-growth in TMTT (+40%). However, the bottom line was messy: GAAP EPS plummeted to $0.11 due to substantial litigation expenses and a $100M impairment on the JenaValve investment. While adjusted EPS of $0.58 met targets, adjusted operating margins compressed significantly to 23.7% (down from ~29% in Q1) as the company ramped SG&A to support new therapies.
🐂 Bull Case
TAVR growth has re-accelerated impressively, moving from +3.8% in Q1 to +12.0% in Q4. Management cites intentional treatment of severe aortic stenosis and expanding evidence (PARTNER 3) as drivers, with the CMS NCD reconsideration acting as a major potential catalyst for 2026.
Transcatheter Mitral and Tricuspid Therapies (TMTT) sales grew over 40% to $156M. With the recent FDA approval of SAPIEN M3 and continued EVOQUE adoption, this segment is rapidly becoming a material profit contributor rather than just a science project.
🐻 Bear Case
Operating leverage has disappeared. SG&A expenses ballooned to 38.4% of sales (up from 35.5% last year), and Adjusted Operating Margin collapsed sequentially to 23.7%. The company is spending heavily to 'amplify patient access,' trading near-term profitability for growth.
A $99.8M impairment charge related to JenaValve Technologies—previously touted as a strategic acquisition target—raises serious questions about the company's capital allocation and the viability of that specific aortic regurgitation technology.
⚖️ Verdict: ⚪
Neutral/Cautious. The top-line acceleration is undeniably positive, proving the TAVR market isn't saturated. However, the heavy cost of growth (margins down ~500bps sequentially) and messy GAAP results (litigation/impairments) muddy the picture. 2026 looks promising only if margins rebound as guided.
Key Themes
TAVR Momentum Returns
After a sluggish start to 2025, TAVR is firing on all cylinders. Q4 sales hit $1.16B (+12% YoY), driven by stable pricing and comparable growth in the U.S. and internationally. The 10-year PARTNER 2 data and 7-year PARTNER 3 data are solidifying the clinical standard, countering competitive fears.
JenaValve Impairment & Strategy Risk
Edwards recorded a $99.8M impairment on its JenaValve investment in Q4. This is a sharp reversal from Q3/Q2 narratives where JenaValve was a key acquisition target to address aortic regurgitation. This write-down suggests either regulatory roadblocks or disappointing technology performance.
TMTT Portfolio Expansion
TMTT remains the fastest-growing segment, up >40% to $156M. The narrative has shifted from single-product reliance to a portfolio approach: PASCAL (repair), EVOQUE (tricuspid replacement), and now SAPIEN M3 (mitral replacement) which recently received FDA approval. Guidance for 2026 expects TMTT to grow another 35-45%.
Litigation Costs
Intellectual property litigation expenses exploded to $208.6M in Q4 (vs $12.6M prior year). While treated as a non-recurring adjustment, cash outflows of this magnitude for legal defense reduce capital available for buybacks or R&D.
NCD Reconsideration Catalyst
CMS has formally opened the reconsideration of the National Coverage Determination (NCD) for TAVR. This is a critical regulatory unlock that could improve timely access to therapy and equitable care, potentially expanding the addressable market in the U.S. for 2026.
Other KPIs
Decelerating significantly. Down from 27.5% in Q3 and 29.1% in Q1. While management claims this was 'in line with guidance,' the sequential compression highlights the high cost of sales support and R&D required to defend TAVR share and launch TMTT products.
Accelerating in absolute terms. Up from $145M in Q3 and $134M in Q2. The segment is annualizing at over $600M, validating the diversified structural heart strategy.
Stable. Growth of 4% reported (2% constant currency) indicates this remains a mature, cash-cow segment. Adoption of RESILIA therapies continues to drive mix shift.
Guidance
Stable/Confident. Management expressed 'increased confidence' in this range. Implicitly, TMTT growth of 35-45% will layer on top of steady high-single-digit TAVR growth.
Accelerating. The midpoint ($2.97) implies ~16% growth over FY25 Adjusted EPS of $2.56. This relies heavily on operating margin expanding back to the high end of 28-29%, a steep climb from Q4's 23.7%.
Accelerating. Implies 35-45% growth off the FY25 base (~$550M). This confirms EVOQUE and SAPIEN M3 are expected to ramp aggressively.
Stable. At the midpoint ($1.59B), this represents roughly flat to slightly up sequential performance vs Q4's $1.57B, consistent with seasonality.
Key Questions
JenaValve Write-down Specifics
The $99.8M impairment on JenaValve is a major red flag given the prior acquisition narrative. Is the acquisition off the table, or has the technology failed to meet clinical milestones?
Operating Margin Bridge
Q4 adjusted operating margin was 23.7%. FY26 guidance calls for margins at the high end of 28-29%. What specific cost levers or volume leverage will drive a ~500bps margin recovery in just a few quarters?
Litigation Persistence
With over $200M in litigation expenses this quarter, are these matters largely settled, or should investors expect continued legal cash outflows in 2026?